KINGSTON, ON. Queen's University medical researchers today released some key findings from the first study of its kind done in Canada on the impact of colds and flu on school absenteeism, the workplace, and the economy.
The researchers reviewed more than 80 published clinical trials, studies and research projects representing the work of over 300 researchers from more than 100 universities and institutions.
In their report entitled "Why the Common Cold and Flu Matter", the researchers found:
Prevention can play a role in reducing the spread of illnesses. Queen's researchers say that school-aged children and young adults play a significant role in the spread of respiratory illnesses. In the U.S. the Centre for Disease Control and Prevention pegs missed school days as a result of colds at 22 million a year.
Studies by SDI, a research agency that tracks colds and flu in North America, have shown that there is an annual spike in colds and flu within the first two weeks of students' return to school in September, something supported by Queen's researchers who cite a sharp increase in pediatric asthma cases as a result of rhinovirus infection, the primary cause of colds. They point out that young children with respiratory symptoms play a major role in spreading colds to family and friends and, "...school-age children have been shown to introduce rhinovirus infections into their families 3 times more frequently than working adults."
But adults also play a significant role in the spread of infection. Queen's researchers found that the U.S. work force goes to work rather than calling in sick resulting in substantial losses of productivity and increased costs:
It costs employers twice as much in productivity losses for employees who come to work sick than for those who stay home. All of this infection adds up to a significant economic cost as researchers cite direct costs due to lost productivity from colds at $25 billion in the U.S. Taking into consideration both indirect (lost productivity) and direct (doctor visits and medicine) costs, of colds, the figure in the U.S. annually is $40 billion
Researchers conclude that, "Preventative measures that result in even a modest reduction in colds and flu would have a significant impact on reducing costs to the healthcare system and impact on the economy."
The study was conducted by the research arm of the Department of Family Medicine at Queen's University in Kingston, Ontario. The study was supported by an independent educational grant from Afexa Life Sciences, the maker of COLD-FX(r), a cold and flu treatment.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.